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Purpose: The aim of this study was to evaluate the prognostic factors for survival in 
patients treated surgically for transitional cell carcinoma of the upper urinary tract 
(UUT-TCC).
Materials and Methods: We retrospectively reviewed the medical records of 87 patients 
(64 men and 23 women, mean age of 62.2 years) with UUT-TCC who had undergone 
radical nephroureterectomy at our institution between June 1994 and June 2009. The 
median follow-up period was 32 months. The prognostic significance of various clin-
icopathological variables for recurrence-free and cancer-specific survival was analyzed 
by using univariate and multivariate analysis.
Results: Of the total 87 patients, 21 patients (24.1%) developed local recurrence or dis-
tant metastasis and 16 patients (18.4%) died of disease during the follow-up period. 
The 5-year recurrence-free and cancer-specific survival rates were 74.6% and 75.2%, 
respectively. In the univariate analysis, hydronephrosis, T stage, N stage, and lympho-
vascular invasion (LVI) were significant prognostic factors for recurrence-free and can-
cer-specific survival. In the multivariate analysis, T stage and LVI were independent 
prognostic factors for recurrence-free and cancer-specific survival.
Conclusions: The T stage and LVI are independent prognostic factors for recurrence- 
free and cancer-specific survival in patients with UUT-TCC treated by radical nephro-
ureterectomy. These findings would be helpful for guiding decisions about adjuvant 
therapies and the surveillance interval.
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INTRODUCTION
Transitional cell carcinoma of the upper urinary tract 
(UUT-TCC) is a relatively uncommon disease, accounting 
for 5% to 6% of all urothelial carcinomas. Radical nephrour-
eterectomy with bladder cuff excision has been considered 
as the standard treatment for UUT-TCC [1-3]. However, 
UUT-TCC is known to have a higher recurrence rate even 
after radical surgery, which may be due in part to the diffi-
culty in early detection of the tumor, the thinner muscular 
and submucosal layers, and the absence of serosa in the up-
per urinary tract [4,5].
　Tumor stage, grade, and surgical procedure performed 
have been documented as the major prognostic factors in 
patients with UUT-TCC [6-9]. In addition, patient age, tu-
mor size and architecture, tumor location, tumor multi-
plicity, lymphovascular invasion (LVI), and a previous his-
tory of bladder cancer have been suggested as potential 
prognostic factors [1,9-11]. However, the influence of these 
potential prognostic factors for UUT-TCC remains less 
clear. A clear knowledge of these prognostic indicators of 
tumor recurrence and progression at the time of surgery 
would allow better prognostic evaluation and approach.
　In this study, we retrospectively reviewed our single- 
center experience in patients with UUT-TCC to identify 
the prognostic factors that predict recurrence-free and can-
cer-specific survival in patients with UUT-TCC after radi-
cal nephroureterectomy. Korean J Urol 2011;52:310-316
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TABLE 1. Clinicopathological data of the 87 patients included in 
the study
Characteristics No. of patients (%)
Age (yr)
　≤65 46 (52.9)
　＞65 41 (47.1)
Gender
　Male 64 (73.6)
　Female 23 (26.4)
Smoking history
　Smoker 57 (65.5)
　Nonsmoker 30 (34.5)
Previous history of bladder cancer
　Absent 81 (93.1)
　Present 6 (6.9)
Concomitant bladder cancer
　Absent 78 (89.7)
　Present   9 (10.3)
Hydronephrosis
　0 27 (31.0)
　11  ( 1 . 1 )
　2 25 (28.7)
　3 19 (21.8)
　4 15 (17.2)
Body mass index (BMI) (kg/m
2)
　＜25 54 (62.1)
　25-29.9 30 (34.5)
　≥30 3 (3.4)
Tumor location
　Renal pelvis 48 (55.2)
　Ureter 33 (37.9)
　Both 6 (6.9)
Tumor multiplicity
　Single 81 (93.1)
　Multiple 6 (6.9)
T stage
　Ta 15 (17.2)
　T1 29 (33.3)
　T2 12 (13.8)
　T3 30 (34.5)
　T4 1 (1.1)
N stage
　N0 77 (88.5)
　N1 3 (3.4)
　N2 6 (6.9)
　N3 1 (1.1)
Grade
　Low 16 (18.4)
　High 71 (81.6)
Lymphovascular invasion
　Absent 66 (75.9)
　Present 21 (24.1)
Squamous differentiation
　Absent 82 (94.3)
　Present 5 (5.7)
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 87 pa-
tients (64 men and 23 women) who had undergone radical 
nephroureterectomy with bladder cuff excision for UUT- 
TCC at our institution between June 1994 and June 2009. 
Mean patient age was 62.2 years (range, 33-85 years). None 
of the patients included in this study had distant meta-
stasis at diagnosis. Regional lymph node dissection was 
performed in patients with clinically apparent lymphaden-
opathy on a preoperative radiologic imaging or in those who 
were suspected of having enlarged lymph nodes intra-
operatively. Tumors were staged by using the 2002 TNM 
staging system [12] and were graded according to the World 
Health Organization (WHO)/International Society of Uro-
logical Pathology (ISUP) grading criteria [13].
　Hydronephrosis was assessed by preoperative imaging, 
and grade of hydronephrosis was estimated according to 
the methods described by Cho et al [14]. The tumors with-
out caliceal or pelvic dilation were classified as grade 0, tu-
mors with pelvic dilation only as grade 1, tumors with mild 
caliceal dilation as grade 2, tumors with severe caliceal di-
lation as grade 3, and tumors with caliceal dilation accom-
panied by renal parenchymal atrophy as grade 4.
　Patient follow-up was relatively uniform and included 
basic laboratory examinations, chest x-ray, cystoscopy, 
and urine cytology every 3 months for the first 2 years, ev-
ery 6 months for the subsequent 2 years, and then yearly 
thereafter. Abdominopelvic computed tomography was 
performed annually during follow-up or when clinically 
indicated.
　The 5-year recurrence-free and cancer-specific survival 
rates were analyzed. Disease recurrence was defined as lo-
cal failure in the tumor bed or regional lymph nodes or dis-
tant metastasis. Because bladder recurrence did not affect 
survival in the patients with UUT-TCC, it was not consid-
ered in the analysis of the recurrence-free survival rate in 
this study.
　Univariate and multivariate analyses were performed 
by using the log-rank test and the Cox’s proportional haz-
ards regression model, respectively. The prognostic factors 
assessed were age, gender, smoking history, previous his-
tory of bladder TCC, concomitant bladder TCC, grade of hy-
dronephrosis, body mass index (BMI), tumor location, tu-
mor multiplicity, T stage, N stage, tumor grade, LVI, and 
squamous differentiation. All statistical analyses were 
performed by using SPSS ver. 13.0 (SPSS Inc., Chicago, IL, 
USA). Values of p＜0.05 were considered to be statistically 
significant in all of the analyses.
RESULTS
The clinicopathological characteristics of the 87 patients 
with UUT-TCC are summarized in Table 1. The primary 
tumor was located in the renal pelvis, ureter, or both in 48 
(55.2%), 33 (37.9%), and 6 patients (6.9%), respectively. Six 
patients (6.9%) had a previous history of bladder TCC and 
9 patients (10.3%) had concomitant bladder TCC when the 
UUT-TCC was diagnosed. In the preoperative imaging Korean J Urol 2011;52:310-316
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FIG. 1. Recurrence-free (A) and cancer-specific (B) survival is illustrated for the 87 patients who underwent radical nephroureterectomy
for transitional cell carcinoma of the upper urinary tract.
FIG. 2. Kaplan-Meier recurrence-free survival curves according to hydronephrosis grade (A), T stage (B), N stage (C), and lymphovascular
invasion (D).
studies, 60 patients (69.0%) presented with ipsilateral 
hydronephrosis. The grade of hydronephrosis was 1, 2, 3, 
and 4 in 1 (1.1%), 25 (28.7%), 19 (21.8%), and 15 patients 
(17.2%), respectively. Regional lymph node dissection was 
performed in 49 patients (56.3%) with enlarged lymph no-
des, and 10 revealed lymph node metastasis on patho-
logical examination. The median number of lymph nodes 
removed was 7 (mean, 8.2; range, 1 to 24). A positive surgi-Korean J Urol 2011;52:310-316
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TABLE 2. Univariate analysis of potential prognostic factors for recurrence-free and cancer-specific survival
Variables
p-value
Recurrence-free survival Cancer-specific survival
Age (≤65 vs. ＞65 yr) 0.272 0.197
Gender (Male vs. Female) 0.772 0.618
Smoking history (No vs. Yes) 0.980 0.433
Previous history of bladder cancer (No vs. Yes) 0.608 0.417
Concomitant bladder cancer (No vs. Yes) 0.557 0.183
Hydronephrosis (G0-G2 vs. G3+G4) ＜0.001 0.001
BMI (＜25 vs. ≥25 kg/m
2) 0.572 0.626
Tumor location (Renal pelvis vs. Ureter) 0.826 0.833
Tumor multiplicity (Single vs. Multiple) 0.469 0.815
T stage (Ta-T2 vs. T3+T4) ＜0.001 ＜0.001
N stage (N0 vs. N1-N3) 0.001 ＜0.001
Tumor grade (Low vs. High) 0.066 0.112
Lymphovascular invasion (No vs. Yes) ＜0.001 ＜0.001
Squamous differentiation (No vs. Yes) 0.887 0.942
BMI: body mass index
TABLE 3. Multivariate analysis of potential prognostic factors for recurrence-free and cancer-specific survival
Variables
Recurrence-free survival Cancer-specific survival
Hazards ratio (95% CI) p-value Hazards ratio (95% CI) p-value
Hydronephrosis (G0-G2 vs. G3+G4) 0.244 (0.034-1.762) 0.162 0.248 (0.040-1.520) 0.132
T stage (Ta-T2 vs. T3+T4) 16.489 (2.316-117.409) 0.005 20.025 (2.842-141.101) 0.003
N stage (N0 vs. N1-N3) 0.806 (0.273-2.381) 0.696 0.972 (0.275-3.434) 0.965
Tumor grade (Low vs. High) 2.520 (0.322-19.697) 0.378 1.603 (0.192-13.397) 0.663
LVI (No vs. Yes) 3.859 (1.197-12.438) 0.024 4.655 (1.067-20.316) 0.041
LVI: lymphovascular invasion, CI: confidence interval
cal margin was found in 6 patients (6.9%) on pathological 
examination. Chemotherapy was administered to 19 pa-
tients and radiotherapy at the surgical bed was performed 
in 5 patients.
　The median follow-up period was 32 months (mean, 42.9; 
range, 1 to 131 months). Of the total 87 patients, 21 patients 
(24.1%) experienced recurrence, including 7 with local re-
currence and 14 with distant metastasis. The site of local 
recurrence was retroperitoneal or in the pelvic lymph no-
des, and distant metastasis occurred in the lung, liver, 
bone, contralateral adrenal gland, sigmoid colon, or pelvic 
side wall. Sixteen patients (18.4%) died of disease during 
the follow-up period. Two of them had local recurrence and 
14 had distant metastasis. Among 21 patients with local 
recurrence or distant metastasis after surgery, 12 patients 
received adjuvant chemotherapy. Bladder recurrence was 
found in 16 patients (18.4%), and none of them developed 
local recurrence or distant metastasis or died during the 
follow-up period.
　The 5-year recurrence-free survival rate was 74.6% (Fig. 
1A). The recurrence-free survival rate was lower in pa-
tients with severe hydronephrosis, higher T stage, lymph 
node metastasis, and lymphovascular invasion (Fig. 2). 
The univariate analysis identified that grade of hydro-
nephrosis (p＜0.001), T stage (p＜0.001), N stage (p=0.001), 
and LVI (p＜0.001) were significant prognostic factors for 
recurrence-free survival (Table 2), whereas the multi-
variate analysis indicated that T stage (p=0.005) and LVI 
(p=0.024) were independent prognostic factors (Table 3).
　The 5-year cancer-specific survival rate was 75.2% (Fig. 
1B). The cancer-specific survival rate was lower in patients 
with severe hydronephrosis, higher T stage, lymph node 
metastasis, and lymphovascular invasion (Fig. 3). The uni-
variate analysis revealed that grade of hydronephrosis 
(p=0.001), T stage (p＜0.001), N stage (p＜0.001), and LVI 
(p＜0.001) were significant prognostic factors for cancer- 
specific survival (Table 2), whereas the multivariate analy-
sis demonstrated that T stage (p=0.003) and LVI (p=0.041) 
were independent prognostic factors (Table 3).
DISCUSSION
Although recent literature suggests that endourological 
techniques for UUT-TCC have been associated with the 
preservation of renal function in selected cases, nephrour-
eterectomy with bladder cuff excision is still the standard 
treatment with the highest cancer-specific survival [9]. 
However, UUT-TCC shows a significantly high local fail-Korean J Urol 2011;52:310-316
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FIG. 3. Kaplan-Meier cancer-specific survival curves according to hydronephrosis grade (A), T stage (B), N stage (C), and lymphovascular
invasion (D).
ure even after radical surgery, especially in patients with 
high stage and grade tumors [6]. Because the location of the 
UUT-TCC may hinder early detection, UUT-TCC is more 
likely to be diagnosed as invasive cancers than as bladder 
cancers. Anatomical differences between the bladder and 
ureter or renal pelvis wall also account for differences in 
the higher incidence of invasive UUT-TCC. The thickness 
of the bladder wall is estimated to exceed that of the ureter-
al wall by 2- to 3-fold [15]. The distal ureter is covered by 
3 muscular layers, whereas the more proximal part of the 
ureter contains only 2 relatively thin interlacing layers 
[16]. Urothelial cancer invasion may be correlated with 
muscular wall thickness [5]. This fact highlights the im-
portance of surgical competence and adequate adjuvant 
therapy in patients with a high risk for failure of UUT-TCC. 
Other potential prognostic factors for predicting high risk 
in UUT-TCC should be identified.
　It has been suggested that factors such as T stage, tumor 
grade, tumor location, lymph node involvement, LVI, and 
surgical procedure performed are associated with prog-
nosis [6,9-11,17-19]. T stage and tumor grade probably 
were the best established major prognostic factors in UUT- 
TCC. Hall et al reported 5-year, cancer-specific survival 
probabilities of 100% for patients with Ta/Tis tumors, 92% 
for patients with T1 tumors, 73% for patients with T2 tu-
mors, and 41% for patients with T3 tumors [9]. In the pres-
ent study, T stage was an independent prognostic factor for 
recurrence-free and cancer-specific survival, supporting 
that T stage is one of the most important prognostic factors 
in UUT-TCC.
　With regard to the tumor grade, the 5-year cancer-specif-
ic survival rates are reported to range from 90% to 100% 
for low-grade UUT-TCC and from 28% to 46% for high- 
grade UUT-TCC [20,21]. Moreover, a few studies have in-
dicated the independent prognostic role of tumor grade 
[4,21], suggesting that patients with high-grade cancers 
had at least a 2-fold increased risk of cancer-related death 
compared with those with low-grade tumors. In the present 
study, tumor grade showed marginal significance (p=0.066) 
only for recurrence-free survival. A larger study population 
and longer follow-up period might be needed to clarify the 
prognostic role of tumor grade.
　Several other putative prognostic factors have also been 
proposed with sometimes conflicting results. One of the 
major issues in UUT-TCC is the prognostic role of a pre-
vious history of bladder cancer and concurrent bladder Korean J Urol 2011;52:310-316
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cancer. A previous history of bladder cancer was identified 
in approximately 7% of our cases and from 9% to 20% of pa-
tients in other studies [9,21]. In our analysis, a previous his-
tory of bladder cancer did not show any prognostic sig-
nificance for UUT-TCC. However, Mullerad et al reported 
that a history of bladder cancer was an independent pre-
dictor of cancer-specific survival in multivariate analysis 
[22]. Conversely, Rabbani et al reported that de novo UUT- 
TCC had a 1.67-fold increased risk of cancer-related death 
compared with UUT-TCC after bladder cancer in the mul-
tivariate analysis and they emphasized the prognostic im-
portance of concurrent bladder cancer more than previous 
bladder cancer history [23]. Kang et al reported that the 
presence of concurrent bladder cancer at the time of treat-
ment for UUT-TCC, mostly by nephroureterectomy, was 
an independent predictor of cancer-specific survival [4]. 
However, our study did not show any relationship between 
concurrent bladder cancer and recurrence-free or cancer- 
specific survival.
　With regard to the tumor location, some studies reported 
that patients with cancers arising from the renal pelvis 
have a better cancer-related survival than do those with 
cancers in the ureter, and tumor site is an independent pre-
dictor of cancer-specific survival [21,24]. Such results may 
be explained by the presence of a thin layer of adventitia 
surrounding the ureter, which contains an extensive 
plexus of ureteral blood vessels and lymphatics that makes 
tumor invasion easier. The other possible reason is that the 
renal parenchyma and perihilar adipose tissue surrounding 
the renal pelvis may act as a barrier against early spread 
[15,25]. Conversely, van der Poel et al demonstrated that 
patients with tumors in the renal pelvis and proximal ure-
ter were 2.5 times as likely to die of disease as were those 
with tumors in the distal ureter [5]. In our series, there was 
no significant difference in recurrence-free or cancer-spe-
cific survival between renal pelvis and ureteral cancers.
　Novara et al demonstrated that tumor multiplicity with-
in the UUT-TCC was an independent predictor of cancer- 
specific survival [26]. The authors suggested that these fea-
tures strongly reconfirmed the panurothelial nature of the 
disease along with the prognostic role of prior or concomitant 
bladder cancers. In our series, however, tumor multiplicity 
was predictive of neither recurrence-free nor cancer-spe-
cific survival, which was in agreement with other reports 
that failed to demonstrate a significant prognostic role of 
multiplicity in UUT-TCC [4,22].
　The presence of LVI has been reported to be an important 
prognostic factor in UUT-TCC [11,18,19]. Kim et al demon-
strated that LVI was an independent prognostic factor for 
recurrence-free and cancer-specific survival in patients 
with localized UUT-TCC after nephroureterectomy [11]. 
Hong et al also suggested LVI as an independent prognostic 
factor for recurrence-free survival in patients with UUT- 
TCC [19]. LVI was also an independent predictor of re-
currence-free and cancer-specific survival in our series.
　Preoperative hydronephrosis has also been reported as 
an important predictor of UUT-TCC. Brien et al demon-
strated that preoperative evaluation for hydronephrosis 
could identify patients at risk for advanced UUT-TCC, and 
such knowledge might impact the extent of surgery as well 
as the need for perioperative chemotherapy regimens [27]. 
Cho et al found that the grade of hydronephrosis and the 
tumor diameter had a significant influence on the prog-
nosis of UUT-TCC [14,28]. They suggested that ureteral tu-
mors cause gradual ureteral obstruction, resulting in the 
development of hydronephrosis, and that there was a corre-
lation between the hydronephrosis grade and T stage. 
Consequently, severe hydronephrosis may be a poor prog-
nostic factor in UUT-TCC. In the present study, hydro-
nephrosis was associated with recurrence-free and can-
cer-specific survival but failed to have an independent 
prognostic role.
　Our study had several limitations. It was retrospective 
in nature and the size of the study population was smaller 
than a recently reported multicenter study, because we col-
lected our single-center experience of an uncommon disease. 
The follow-up period might not have been long enough. In 
addition, lymph node dissection was not performed in all 
patients. Nevertheless, we believe that the results of our 
study support the already established T stage and LVI as 
independent prognostic factors for recurrence-free and 
cancer-specific survival in patients with UUT-TCC treated 
by radical nephroureterectomy.
CONCLUSIONS
The results of this study have demonstrated that T stage 
and LVI are independent prognostic factors for recurrence- 
free and cancer-specific survival in patients with UUT- 
TCC treated by radical nephroureterectomy. These find-
ings will be helpful for guiding decisions about adjuvant 
therapies and the surveillance interval.
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